Delafloxacin (originally RX-3341) is a fluoroquinolone antibiotic being developed by Rib-X Pharmaceuticals Inc.It is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as MRSA. In contrast to most approved fluoroquinolones which are zwitterionic delafloxacin has an anionic character which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH.
This page contains content from the copyrighted Wikipedia article "Delafloxacin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
